ISPOR Europe 2018
Barcelona, Spain
November, 2018
PCN372
Cancer
Patient-Reported Outcomes & Patient Preference Studies (PRO)
Patient-Reported Outcomes (PRO)
EVIDENCE MAP OF PATIENT REPORTED OUTCOME STUDIES IN NON-HODGKIN LYMPHOMA SINCE 1960
Furber AM1, Martin A2
1Crystallise, East Tilbury, UK, 2Crystallise Ltd., East Tilbury, UK
OBJECTIVES

:
To create an Evidence Map of patient reported outcome (PRO) studies of patients with Non-Hodgkin lymphoma, the geographical settings in which these studies were conducted, and the interventions assessed.

METHODS

:
We searched the heoro.com database (www.heoro.com) for PRO studies in Non-Hodgkin lymphoma published between 1960 and 6th April 2018, and analysed the abstracts identified by the search to determine the names of different PRO tools cited across the range of geographical locations and interventions. We presented the results as an Evidence Map.

RESULTS

:
We found a total of 52 abstracts that reported the use of PRO tools across 27 different countries, almost half of which were published between 2010 and 2018. Of these abstracts, 19 reported the use of EORTC-QLQ-C30, 7 used the EQ-5D and 5 used the SF-36, and 33 other PRO tools were also reported. 16 different interventions were recorded, with traditional chemotherapy regimes being the most reported (15 abstracts) followed by rituximab (9) and radiotherapy (3); other interventions assessed in 1-2 abstracts included ibritumomab, lenalidomide, obinutuzumab, tositumomab and vorinostat. The USA was the most frequent location for the studies, with 13 abstracts, followed by the Netherlands (9), Canada (7) and France (7). Lymphoma stage was most commonly unspecified, but 6 reported refractory stage, 5 aggressive, 4 advanced, 3 low grade, 2 high grade and 1 early stage. The studies most frequently recruited general members of the lymphoma population with no specified age group (36), but 7 abstracts cited an elderly population specifically, 6 assessed survivors, 2 assessed caregivers and 1 assessed children.

CONCLUSIONS

:
PRO studies in Non-Hodgkin lymphoma have most commonly used the EORTC-QLQ-C30 to explore the use of traditional chemotherapy in a generic patient population.